123-I THYROID UPTAKE AT 24, 48, AND 72 HOURS FOLLOWING ADMINISTRATION OF RH-TSH

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。重组人（rh-TSH）是常规用于监测甲状腺癌患者。它的使用刺激甲状腺放射性碘摄取（RAIU）和甲状腺球蛋白释放，而不需要停止甲状腺激素治疗并使患者甲状腺功能减退。在这个问题上，rh-TSH已被FDA批准用于甲状腺癌的治疗及其在各种亚组中的安全性，包括甲状腺功能正常的受试者和结节性甲状腺肿大的患者。在正常甲状腺功能正常的受试者和无毒多结节性甲状腺肿患者中，重组人TSH增加24小时放射性碘摄取（RAIU）。然而，rh-TSH引起的RAIU增加的确切持续时间尚未得到描述。本研究的目的是研究rh-TSH在给药后24、48和72小时对RAIU的影响。此外，我们将检查持续时间和峰值效应，其中最大的RAIU增长是可见的。最终，这可能有助于甲状腺癌的术后管理，因为它将为我们提供一个最佳的时间框架来测量RAIU，以改善甲状腺转移和残留甲状腺床组织的可视化。我们计划招募15名甲状腺和甲状腺功能正常的受试者。我们将给所有受试者0.1 mg的rh-TSH，并在rh-TSH给药后24、48和72小时测量123-I给药后的24小时RAIU。这些信息也将为rh-TSH给药后给予131-I消融甲状腺癌切除后残留甲状腺组织的最佳时间以及减少大结节性无毒甲状腺肿大的大小提供指导。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recombinant human (rh-TSH) is routinely used in the monitoring if patients with thyroid cancer. Its administration stimulates thyroid radioiodine uptake (RAIU) and thyroglobulin release without the need to withdraw thyroid hormone therapy and render the patient hypothyroid. In this matter, a rh-TSH is FDA approved for the management of thyroid cancer and its safety in various subgroups, including euthyroid subjects and in those with nodular goiters, has been established. In normal euthyroid subjects and in patients with non-toxic multinodular goiters recombinant human TSH increases the radioiodine uptake (RAIU) at 24 hours. However, the precise duration of this increase in the RAIU from rh-TSH has not yet been described. The purpose of our study is to examine the effect of rh-TSH on the RAIU at 24, 48, and 72 hours after its administration. In addition, we will examine the duration and peak effect where the greatest increase on the RAIU is seen. Ultimately, this may facilitate post-operative management of thyroid cancer, as it will provide us with an optimal time frame at which to measure RAIU for improved visualization of thyroid metastases and residual thyroid bed tissue. We plan to recruit 15 subjects with normal thyroid glands and normal thyroid function. We will administer 0.1 mg of rh-TSH to all subjects and measure the 24-hour RAIU following the administration of 123-I at 24, 48, and 72 hours after rh-TSH administration. This information will also provide guidance for the optimal time after rh-TSH administration to give 131-I for the ablation if residual thyroid tissue after thyroidectomy for thyroid cancer and to decrease the size of large nodular non-toxic goiters.